Moderna's Raised Guidance Meets a $4 Billion Spending Test as Investors Await 2027 Clarity

Moderna has given investors two very different things to weigh: a brighter near-term sales picture and a multi-year spending commitment whose payoff remains unproven. The tension between the two has become the central question for anyone holding the stock.

The company now expects revenue growth of 15% to 25% for 2026, up from prior guidance of as much as 10%. That upgrade accompanied third-quarter results published on 6 November, which showed revenue of $1.3 billion — a 29% increase over the same period a year earlier — and a GAAP net profit of $0.2 billion, or $162 million.

Yet the shares fell 3.2% on Friday, extending pressure that had already built on Thursday. According to media reports, two factors weighed on sentiment: the higher-than-expected cost outlook and the absence of a formal financial forecast for the coming year, which Moderna had not presented at its analyst day. A weak biotech backdrop added to the drag — most comparable stocks also declined, and Moderna's drop exceeded the median of its sub-sector.

Costs in focus as oncology absorbs capital

At the analyst day, Moderna laid out cash operating costs of roughly $4 billion for 2027, rising to between $4 billion and $4.5 billion annually through 2030. Management identified oncology investment as the main driver, a horizon that stretches well beyond the current fiscal year.

The company also trimmed its expected research and development spending for 2026 to approximately $2.7 billion, down from around $2.9 billion previously planned. For 2026, Moderna additionally anticipates gross margin improvement of about ten percentage points, excluding the impact of a litigation settlement payment.

Goldman Sachs raised its price target on 9 November to $195 from $137, with analyst Salveen Richter keeping a "Neutral" rating on the stock.

Vaccine data offer a counterweight

Arguments for the bullish case extend beyond the guidance hike. Health Canada last week approved both the seasonal influenza vaccine mFLUSIVA and the influenza/COVID-19 combination vaccine mCOFLU for adults aged 50 and older, making Canada the first country to clear both products.

Observational data on mNEXSPIKE, released on Wednesday, added another data point. In a study of older US veterans, the shot showed a relative vaccine effectiveness of 35.9% against medically treated COVID-19 compared with Comirnaty, and 47% against COVID-19-related hospitalizations. Such results could support commercial prospects, though no specific additional revenue can be derived from them.

The next checkpoint

The immediate catalyst is Moderna's participation in the Jefferies Global Health Care Conference on 18 November 2026, confirmed for 11:00 GMT. Commentary on business development there could sharpen expectations, though no new financial forecast is slated for that appearance.

Formal guidance for 2027 will instead arrive with the fourth-quarter 2026 earnings call. Until then, investors must separate reported results from longer-range ambitions — and judge whether the sales momentum now being guided can carry the investment framework management has set out.